Mankind Pharma may partner RDIF for Russian Covid-19 vaccine Sputnik V

As Russian Covid-19 vaccine Sputnik V nears entry into the Indian market, one of the largest drug firms in the country, Mankind Pharmaceuticals, is likely to partner the Russian Direct Investment Fund (RDIF) for distributing it in India.

According to sources, Sputnik V may be priced Rs 500 per dose when it is commercially available. The Centre and RDIF, however, will negotiate prices at which the government will procure the vaccine for the national Covid immunisation drive.

According to sources close to the development, talks are in advanced stages between Mankind Pharma and RDIF to sign a partnership for distribution of the